AbbVie 4Q Revenues: $8.7 billion (+5%) 4Q Earnings: $2.8 billion (loss of $1.8 billion 4Q18)    FY Revenues: $33.3 billion (+2%) FY Earnings: $7.9 billion (+39%) Comments: U.S. HUMIRA sales were $4.0 billion in the quarter, up 10%. Internationally, HUMIRA revenues were $948 million, down 27% due to biosimilar competition. Global IMBRUVICA revenues were $1.3 billion, an increase of 29%, with U.S. sales of $1.1 billion and international profit sharing of $223 million. Global VE...